ERWINAZE Drug Profile

Summary for Tradename: ERWINAZE

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ERWINAZE

Recent Clinical Trials for ERWINAZE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 3
Children's Oncology Group	Phase 3
Ashkan Emadi	Phase 1

See all ERWINAZE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ERWINAZE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ERWINAZE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	4,729,957	2006-10-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ERWINAZE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,287,294	2036-07-08	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,787,671	2038-10-17	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,821,160	2037-03-01	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,933,061	2038-12-21	Patent claims search

Market Dynamics and Financial Trajectory of ERWINAZE

Last updated: February 19, 2026

What is ERWINAZE and its current positioning?

ERWINAZE (asparaginase erwinia chrysanthemi) is a biologic enzyme used to treat acute lymphoblastic leukemia (ALL), particularly in cases with hypersensitivity to E. coli-derived asparaginase. It is marketed by Takeda Pharmaceutical. ERWINAZE received FDA approval in 2011 for pediatric ALL and later expanded to adult indications.

Market size and growth drivers

The global leukemia therapeutics market, which includes ERWINAZE, was valued at approximately $10 billion in 2022. It is projected to reach $14 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.4% (Market Research Future, 2022).

Key factors driving demand:

• Increasing prevalence of ALL, especially among pediatric and young adult populations.
• Rising adoption of biologics over traditional chemotherapies due to improved safety.
• Growing awareness of hypersensitivity management options.

Competitive landscape

ERWINAZE competes primarily with E. coli-derived asparaginase formulations such as Oncaspar (a PEGylated version by Servier) and alternative formulations like native E. coli asparaginase.

Product	Manufacturer	Indication	Formulation	Approval Year	Market Share (2022)
ERWINAZE	Takeda	ALL	Native; Intravenous	2011	25%
Oncaspar	Servier	ALL	PEGylated; Intravenous	1994	55%
E. coli asparaginase	Various	Off-label	Native	Pre-2010	20%

ERWINAZE is favored for hypersensitivity cases where PEGylated versions are contraindicated or ineffective.

Regulatory and supply considerations

• Manufacturing agreements with pediatric hospitals and international regulatory agencies influence availability.
• The supply chain largely depends on bacterial fermentation processes producing asparaginase, with occasional shortages impacting sales.

Financial trajectory and sales performance

ERWINAZE's sales in 2022 are estimated at $250 million globally, with North America accounting for roughly 50%. The product's revenue has grown approximately 10% annually since 2018, driven by increased treatment adoption.

Key financial drivers:

• High treatment cost per patient (~$40,000/course).
• Treatment duration of 6-8 months affects revenue consistency.
• Contractual agreements for supply with hospitals contribute to revenue security.

Pricing trends and reimbursement landscape

Price per treatment cycle in the US ranges from $35,000 to $45,000. Payer coverage is generally favorable for biologics with FDA approval, though formulary restrictions apply in some regions.

Insurance reimbursement rates have remained steady but face pressure from health technology assessments. International markets exhibit variable pricing, with lower rates in Europe and emerging markets.

Impact of biosimilars and innovations

To date, no biosimilars have entered the market for ERWINAZE. However, research into alternative enzyme formulations and humanized variants could influence future market share. The arrival of competing products could exert downward pressure on prices and sales.

Opportunities and risks

Opportunities:

• Expanding indications, such as for adult relapsed/refractory ALL.
• Developing novel formulations with longer half-life to improve compliance.
• Growing awareness of hypersensitivity issues can boost ERWINAZE utilization.

Risks:

• Entrenched presence of PEGylated asparaginase competitors.
• Manufacturing complexities and supply chain issues.
• Potential regulatory restrictions on enzyme production.

Conclusion

ERWINAZE sustains a niche position driven by hypersensitivity management in ALL therapy. Its revenue growth depends on expanding indications, maintaining supply reliability, and navigating competitive pressures. Without biosimilar competition to date, its market share remains relatively stable, though future entries could reshape dynamics.

Key Takeaways

• The global leukemia biologics market is projected to grow at 6.4% CAGR through 2027.
• ERWINAZE's estimated sales reached $250 million in 2022, with a 10% annual growth rate since 2018.
• Competition from PEGylated asparaginase dominates, but ERWINAZE's role remains significant in hypersensitivity cases.
• Supply chain stability and innovative formulations will influence future growth.
• Regulatory environment and reimbursement policies are critical for maintaining financial performance.

FAQs

1. What are the primary competitors of ERWINAZE?
   Answer: Oncaspar by Servier and native E. coli asparaginase formulations.

2. How does ERWINAZE's pricing compare internationally?
   Answer: In the US, treatment cycles cost $35,000–$45,000; lower prices are common in Europe and emerging markets.

3. Are biosimilars expected for ERWINAZE?
   Answer: None are currently approved, but development efforts are ongoing.

4. What factors could impact ERWINAZE's future sales?
   Answer: Competitive biosimilars, supply chain disruptions, regulatory changes, and clinical trials introducing alternative therapies.

5. Has ERWINAZE received approvals for adult leukemia treatment?
   Answer: Yes, its indications have expanded to include adult patients, contributing to growth.

---

References

[1] Market Research Future. (2022). Leukemia Therapeutics Market Research Report.
[2] FDA. (2011). FDA Approval of ERWINAZE for Pediatric ALL.
[3] Takeda Pharmaceutical. (2022). Annual Report.
[4] IMS Health. (2022). Global Oncology Drug Market Data.